Ilhan Lim

8PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersInstruments and techniquesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Accelerators
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 21, 2026
Protein expression of glucose metabolism and somatostatin receptor between primary tumor and distant metastasis in differentiated thyroid cancer.

|Oct 09, 2025
Clinical perspective on targeted alpha therapy using 225Ac.

Ilhan Lim

|Sep 26, 2022
The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.

Joon Ho Choi, Ilhan Lim, Byung Hyun Byun

|Feb 08, 2022
The Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report.

Inki Lee, Ilhan Lim, Byung Hyun Byun

|Apr 03, 2021
Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab.

Chul-Hee Lee, Ilhan Lim, Sang-Keun Woo

|Jan 21, 2021
A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer.

Inki Lee, Ilhan Lim, Byung Hyun Byun

Pageof 2

Frequent Collaborators

2 joint publications

Inki Lee

2 joint publications

Byung Il Kim

2 joint publications

Chang Woon Choi

2 joint publications

Kyo Chul Lee